Defining the optimal dose for remote ischaemic preconditioning in adult patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass: a randomised controlled trial

Not Applicable

• Conditions: Coronary Artery Bypass Graft Surgery; Cardiovascular - Coronary heart disease

• Registration Number: ACTRN12610000876099
• Lead Sponsor: Medical Research Institute of New Zealand

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-10-19
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Stopped early
• Sex: All
• Target Recruitment: 96

Inclusion Criteria

Undergoing coronary artery bypass graft surgery with cardiopulmonary bypass

Exclusion Criteria

1. documented ejection fraction <50%,
2. concurrent valvular surgery,
3. myocardial infarction within 21 days,
4. possible radial artery harvesting,
5. planned cross-clamp fibrillation,
6. >85 years of age,
7. peripheral vascular disease affecting the upper limbs
8. taking the sulphonylurea glibenclamide

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Defining the optimal dose of remote ishaemic preconditioning by determining which number of cycles generates the smallest area under the curve of high sensitivity troponin[6, 12, 24, 48 and 72 hours post removal of the aortic cross clamp at the end of cardiopulmonary bypass]

Secondary Outcome Measures

Name	Time	Method
Treatment success measured by ICU-free hours to 48 hours after ICU admission[48 hours after ICU admission]